HOME Research Insight Key Players in the Blood Screening Market Focus on Agreements, Partnerships, and Collaborations



Key Players in the Blood Screening Market Focus on Agreements, Partnerships, and Collaborations


The blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7% during the forecast period. Factors such as increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases are driving the growth of the blood screening market.

The blood screening market is consolidated in nature due to the presence of a few large players. The prominent players in the blood screening market include Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Siemens Healthineers (Germany).

Grifols held the leading position in the global blood screening market in 2015. The company has a broad product portfolio of laboratory diagnostic tools. In order to maintain its market share, the company has adopted product approvals strategy. For instance, in June 2016, Grifols and Hologic, Inc. (U.S.) announced the U.S. FDA approval of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency’s Investigational New Drug (IND) study protocol. This type of product approval has enhanced the company’s portfolio of blood screening products. In addition, Grifols also focuses on agreements and acquisitions to strengthen its position in the market. In March 2014, Grifols signed an agreement with the Japanese Red Cross to conduct NAT testing of Japan’s blood supply. According to this agreement, the Japanese Red Cross will use the Procleix Panther Platform to screen approximately 5.3 Million blood donations each year for HIV and hepatitis. This helped the company to maintain its leadership position in the NAT testing market.

Roche Diagnostics accounted for the second-largest share in the global blood screening market in 2015. The company is one of the leading healthcare providers in the in vitro diagnostics segment. The company focuses on new product launches as its key strategy to exploit growth opportunities in the blood screening market. For instance, in June 2016, Roche launched the LightMix Modular Zika Virus Assay (CE) in markets accepting the CE mark for patients with signs and symptoms of the Zika virus infection. This new test is run on the large installed base of Roche’s MagNA Pure 96 system for nucleic acid purification and LightCycler 480 or cobas z 480 instruments for real-time PCR. Moreover, the company also focuses on developing tests for HIV, HBV, and HCV, which is an emerging trend in the blood screening market.

The key strategies followed by most companies in the blood screening market are product launches, approvals, agreements, acquisition, and expansion. The product launches strategy accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some of the leading players that adopted this strategy include Roche Diagnostics, Abbott Laboratories, bioMérieux, and Bio-Rad Laboratories. Regulatory approvals accounted for the second-largest share of the overall growth strategies adopted by players in this market. Ortho Clinical Diagnostics, Grifols, and Beckman Coulter, Inc. are the leading manufacturing companies that adopted this strategy.

Related Reports:

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports